KPTI — Karyopharm Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1503802 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-20

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 33,432,000 32,347,000 -22,526,000 -67,023,000 111,317,000 54,980,000 441,485,000
Mar 2026 35,066,000 33,721,000 -26,760,000 -22,392,000 131,417,000 90,850,000 397,063,000
Dec 2025 34,079,000 32,595,000 -17,844,000 -102,198,000 108,416,000 60,540,000 401,342,000
Sep 2025 44,044,000 41,931,000 -15,220,000 -33,127,000 96,232,000 37,672,000 365,490,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-65,347,000
Investing CF
$2,969,000
Financing CF
$78,596,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.09
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,848,914,000
Inventory
$3,994,000
Receivables
$29,871,000
ST Investments
$10,125,000
EBIT TTM
$-175,448,000
Pretax Income TTM
$-224,772,000
Interest Exp TTM
$49,324,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$146,620,992
EBITDA
$-82,201,000
Free Cash Flow
$-29,674,250
Enterprise Value
$299,942,144
Total Cash
$65,105,000
Total Debt
$328,529,984
Shares Out
22,681,460
Trailing EPS
$-14.33
Book Value
$-14.56
ROE
—
ROA
-47.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 146,067,000 -90,707,000 -196,039,000 108,416,000 401,342,000 -292,926,000 -75,369,000
Dec 2024 145,237,000 -119,443,000 -76,422,000 164,418,000 350,435,000 -186,017,000 -127,486,000
Dec 2023 146,033,000 -129,540,000 -143,099,000 240,438,000 376,644,000 -136,206,000 -92,723,000
Dec 2022 157,074,000 -142,202,000 -165,291,000 358,172,000 374,828,000 -16,656,000 -149,554,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$146,621,000
NetIncome TTM
$-224,740,000
OpCashFlow TTM
—
Assets (Latest)
$111,317,000
Forward EPS
$-2.82

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $1.26T $1415.55 —
JNJ JOHNSON & JOHNSON $670.92B $278.70 —
ABBV AbbVie Inc. $517.59B $292.82 —
MRK Merck & Co., Inc. $353.44B $143.37 —
NVS NOVARTIS AG $302.46B $159.13 —

News headlines (Yahoo Finance, 1h cache)

Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
2026-11-04 14:01 · Yahoo
Karyopharm, deep in debt, to sell itself in bankruptcy
2026-11-02 17:07 · Yahoo
Karyopharm Therapeutics Files for Chapter 11 Bankruptcy and Agrees to Planned Merger with Ayrmid
2026-11-02 15:52 · Yahoo
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
2026-11-02 12:10 · Yahoo
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 20:05 · Yahoo
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
2026-09-11 09:37 · Yahoo
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 20:05 · Yahoo
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
2026-08-20 13:43 · Yahoo
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...
2026-08-13 23:09 · Yahoo
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
2026-08-13 12:50 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.